Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-02-19

FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Hisun Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for Irbesartan and Hydrochlorothiazide by Hisun Pharmaceuticals USA Inc., updating the product's labeling and approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IRBESARTAN AND HYDROCHLOROTHIAZIDE (irbesartan and hydrochlorothiazide)

Snippet

SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)